Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424942 | 0.90 | MEN1 (0.43) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL2428331 | 0.87 | KMT2A (0.51) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL2422166 | 0.86 | CYP1A2 (0.49) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL2425516 | 0.86 | MEN1 (0.54) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL2423026 | 0.84 | MAPK9 (0.51) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL6434264 | 0.84 | MEN1 (0.50) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL2425463 | 0.84 | MEN1 (0.50) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL4201447 | 0.83 | MEN1 (0.41) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL2419346 | 0.83 | MEN1 (0.49) | MEN1KMT2AG6PDMAPK9MAPK10 | |
| SCHEMBL2421919 | 0.83 | MEN1 (0.47) | MEN1KMT2AG6PDMAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | MEN1 3205/4885KMT2A 2101/4885G6PD 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.